Shares of Hemogenyx Pharmaceuticals PLC (LON: HEMO) plunged 11% following the company’s announcement yesterday that it had drawn down £12 million from a convertible note financing facility with Mint Capital Ltd.
Investors sold the biotech company’s shares in anticipation of the dilution that will occur after the issuance of 7,741,935 shares as an arrangement fee to Mint Capital after receiving the above funds.
The biotechnology firm intends to use at least £6 million of the funds raised to fund the work needed to obtain clinical proof of concept for HEMO-CAR-T to treat acute myeloid leukaemia (AML).
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Hemogenyx also revealed significant progress in developing its CDX antibody candidate and its HEMO-CAR-T drug candidate.
The company also reported positive progress in its cell therapy platform’s pre-clinical studies, which is a novel method for programming immune cells to treat both viral infections, such as COVID-19 and specific cancers (the “CBR Platform”).
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
“Our various product candidates have shown great results in our laboratory research and testing, and the Company is poised to move our product candidates into proof of concept and clinical studies. The use of the Financing Facility will enable Hemogenyx Pharmaceuticals to move our life-saving technologies forward rapidly, placing the Company in a highly competitive position in the treatment of cancer and viral diseases. This without doubt will be in the best interest of patients as well as the Company’s shareholders.”
Hemogenyx share price
Hemogenyx shares fell 11% to trade at 7p having fallen from Wednesday’s closing price of 7.7p.
